Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022.
Lidia GattoEnrico FranceschiAlicia TosoniVincenzo Di NunnoStefania BartoliniAlba Ariela BrandesPublished in: Expert opinion on drug discovery (2023)
: GBM molecular heterogeneity and brain anatomical characteristics critically restrain drug effectiveness. Nevertheless, stimulating insights for future research and drug development come from innovative treatment strategies for GBM, such as multi-specific "off-the-shelf" CAR-T therapy, oncolytic viral therapy and autologous dendritic cell vaccination. Disappointing results from targeted therapies-clinical trials are mainly due to complex interferences between signaling pathways and biological processes leading to drug resistance: hence, it is imperative in the future to develop combinatorial approaches and multimodal therapies, such as dual block of PI3K and MAPK signaling or PI3K/MTOR inhibition, to improve therapeutic benefit and survival.
Keyphrases
- signaling pathway
- clinical trial
- dendritic cells
- current status
- randomized controlled trial
- systematic review
- pi k akt
- sars cov
- cell proliferation
- bone marrow
- white matter
- immune response
- pain management
- emergency department
- multiple sclerosis
- combination therapy
- resting state
- chronic pain
- platelet rich plasma
- cerebral ischemia
- free survival
- induced apoptosis
- phase ii
- subarachnoid hemorrhage